Remove Pharma Remove Pharmacology Remove Prescription Remove Safety
article thumbnail

How NLP Helps Life Sciences Companies Unlock Insights from Drug Labels

PM360

Drug labels hold value for life sciences companies because they are rich, extensive documents that can be used across labeling, regulatory, safety, and medical affairs. Typically, a drug label refers to any information provided with prescription drugs, as requested by regulators such as the U.S.

article thumbnail

The Buyers Guide to Supercharging your Pharma Field Force Sales Performance 

Quantified

For Pharma, the pandemic touched and disrupted every part of the business and created a unique challenge for the field force. On the one hand, patient need for access and business need to restore and accelerate sales and prescription momentum have never been more critical. 6 Steps to Improving Pharma Sales.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why aren’t digital pills taking off?

Pharmaceutical Technology

Yet, despite the landmark FDA approval, digital pills have not exploded in pharma. But the pharmacology to quantify adherence also depends on race, gender, weight, and other factors. The FDA has also cleared Akilii’s EndeavorRx , a prescription-only medical device for attention deficit hyperactivity disorder.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). Some women are also wary of using pharmacologic options when addressing sexual dysfunction, says Kingsberg.

article thumbnail

Legal challenges put off label use of gender affirming care drugs in jeopardy

Pharmaceutical Technology

However, health specialists refute most safety concerns for the use of drug classes as part of gender affirming care, citing years of research and care. With restricted access and reduced prescription of puberty blockers and hormone therapies, the impact on pharmaceutical companies manufacturing these therapies also remains unclear.

Ethics 144